U.S. Pharmaceuticals & Biotech Top Stock Picks from Analysts

Cibus

Market Cap: US$72.7m

An agricultural biotechnology company, develops and licenses gene edited plant traits using gene editing technologies to enhance farming productivity or produce renewable low carbon plant products.

PMV Pharmaceuticals

Market Cap: US$72.1m

A precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer.

Artiva Biotherapeutics

Market Cap: US$71.3m

A clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.

Clene

Market Cap: US$70.2m

A clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.

aTyr Pharma

Market Cap: US$69.6m

A clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.

Adicet Bio

Market Cap: US$68.5m

A clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.

Immix Biopharma

Market Cap: US$67.9m

A clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.

Plus Therapeutics

Market Cap: US$67.3m

A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer.

Jasper Therapeutics

Market Cap: US$67.0m

A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.

MiNK Therapeutics

Market Cap: US$66.3m

A clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases.

Gain Therapeutics

Market Cap: US$65.4m

A biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia.

Precision BioSciences

Market Cap: US$64.1m

A clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States.

Aligos Therapeutics

Market Cap: US$63.3m

A clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases.

OS Therapies

Market Cap: US$63.3m

A clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States.

MediciNova

Market Cap: US$61.3m

A biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States.

Barinthus Biotherapeutics

Market Cap: US$60.9m

A clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases.

Genenta Science

Market Cap: US$59.7m

A clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.

Camp4 Therapeutics

Market Cap: US$59.5m

A clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases.

Jupiter Neurosciences

Market Cap: US$59.2m

A clinical stage research and development pharmaceutical company, develops resveratrol platform products for the treatment of neuroinflammation.

Veru

Market Cap: US$57.0m

A late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS).

Acrivon Therapeutics

Market Cap: US$56.9m

A clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform.

INmune Bio

Market Cap: US$56.6m

A clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States.

Cue Biopharma

Market Cap: US$55.6m

A clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells in the United States.

MAIA Biotechnology

Market Cap: US$54.8m

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer.

Nasus Pharma

Market Cap: US$54.4m

Operates as a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.

Karyopharm Therapeutics

Market Cap: US$53.8m

A commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States.

Serina Therapeutics

Market Cap: US$53.8m

A biotechnology company, develops drugs to treat neurological diseases and pain.

PolyPid

Market Cap: US$52.8m

A clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.

Inotiv

Market Cap: US$51.9m

Provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally.

Earth Science Tech

Market Cap: US$51.2m

Together with its subsidies, focuses on health and wellness industry.

BioXcel Therapeutics

Market Cap: US$50.5m

Together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States.

Actinium Pharmaceuticals

Market Cap: US$49.9m

Develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.

Estrella Immunopharma

Market Cap: US$49.7m

A clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.

RenovoRx

Market Cap: US$49.1m

A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.

FibroGen

Market Cap: US$48.2m

A biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs.

PDS Biotechnology

Market Cap: US$48.0m

A clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies.